| Literature DB >> 32269302 |
Rupesh Raina1,2, Jirair K Bedoyan3, Uta Lichter-Konecki4, Philippe Jouvet5, Stefano Picca6, Nicholas Ah Mew7, Marcel C Machado8, Ronith Chakraborty9, Meghana Vemuganti10, Manpreet K Grewal11, Timothy Bunchman12, Sidharth Kumar Sethi13, Vinod Krishnappa9,14, Mignon McCulloch15, Khalid Alhasan16, Arvind Bagga17, Rajit K Basu18, Franz Schaefer19, Guido Filler20, Bradley A Warady21.
Abstract
Hyperammonaemia in children can lead to grave consequences in the form of cerebral oedema, severe neurological impairment and even death. In infants and children, common causes of hyperammonaemia include urea cycle disorders or organic acidaemias. Few studies have assessed the role of extracorporeal therapies in the management of hyperammonaemia in neonates and children. Moreover, consensus guidelines are lacking for the use of non-kidney replacement therapy (NKRT) and kidney replacement therapies (KRTs, including peritoneal dialysis, continuous KRT, haemodialysis and hybrid therapy) to manage hyperammonaemia in neonates and children. Prompt treatment with KRT and/or NKRT, the choice of which depends on the ammonia concentrations and presenting symptoms of the patient, is crucial. This expert Consensus Statement presents recommendations for the management of hyperammonaemia requiring KRT in paediatric populations. Additional studies are required to strengthen these recommendations.Entities:
Year: 2020 PMID: 32269302 DOI: 10.1038/s41581-020-0267-8
Source DB: PubMed Journal: Nat Rev Nephrol ISSN: 1759-5061 Impact factor: 28.314